Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr;6(2):74-7.
doi: 10.1177/1756287213513488.

The Prostate Health Index: a new test for the detection of prostate cancer

Stacy Loeb  1 , William J Catalona  2
Affiliations
Review

The Prostate Health Index: a new test for the detection of prostate cancer

Stacy Loeb et al. Ther Adv Urol. 2014 Apr.

Abstract

A major focus in urologic research is the identification of new biomarkers with improved specificity for clinically-significant prostate cancer. A promising new test based on prostate-specific antigen (PSA) is called the Prostate Health Index (PHI), which has recently been approved in the United States, Europe and Australia. PHI is a mathematical formula that combines total PSA, free PSA and [-2] proPSA. Numerous international studies have consistently shown that PHI outperforms its individual components for the prediction of overall and high-grade prostate cancer on biopsy. PHI also predicts the likelihood of progression during active surveillance, providing another noninvasive modality to potentially select and monitor this patient population. This article reviews the evidence on this new blood test with significant promise for both prostate cancer screening and treatment decision-making.

Keywords: PHI; PSA; free PSA; prognosis; prostate cancer; prostate health index; screening.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

    1. American Cancer Society (ACS) (2013) Cancer facts & figures 2013 [online]. Atlanta, GA: American Cancer Society; Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/docume... (accessed 1 August 2013).
    1. Catalona W., Bartsch G., Rittenhouse H., Evans C., Linton H., Amirkhan A., et al. (2003) Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170: 2181–2185 - PubMed
    1. Catalona W., Partin A., Sanda M., Wei J., Klee G., Bangma C., et al. (2011) A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185: 1650–1655 - PMC - PubMed
    1. Ferro M., Bruzzese D., Perdona S., Marino A., Mazzarella C., Perruolo G., et al. (2013) Prostate Health Index (PHI) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2–10 ng/ml. PLoS One 8: e67687. - PMC - PubMed
    1. Lazzeri M., Haese A., Abrate A., de la Taille A., Redorta J., McNicholas T., et al. (2013a) Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 112: 313–321 - PubMed